- Home
- LXRX vs VALN Comparison
LXRX vs VALN Comparison
Compare LXRX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | VALN |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.9M | 537.8M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXRX | VALN |
|---|---|---|
| Price | $1.69 | $6.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.15 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 2.6M | 105.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.36 | $5.43 |
| 52 Week High | $1.83 | $12.25 |
Technical Indicators
Market Signals| Indicator | LXRX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 28.50 |
| Support Level | $1.08 | $5.69 |
| Resistance Level | $1.81 | $6.73 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.01 | -0.38 |
| Stochastic Oscillator | 65.00 | 5.72 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.